CRISPR Therapeutics AG (CRSP)

45.18 +1.33 (+3.03%) USD  |  NASDAQ  |  Mar 29, 16:00
45.30 +0.12 (+0.27%) After-Hours: 20:00
More
CRISPR Therapeutics AG Key Stats
Financials

Income Statement

Revenue (TTM) 0.436M
Net Income (TTM) -650.18M
EBIT (TTM) Upgrade
EBITDA (TTM) Upgrade
Revenue (Quarterly) 0.006M
Net Income (Quarterly) -110.58M
EBIT (Quarterly) Upgrade
EBITDA (Quarterly) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
EBITDA (Quarterly YoY Growth) Upgrade

Common Size Statements

EPS Diluted (TTM) -8.37
EPS Basic (TTM) Upgrade
Shares Outstanding 78.65M

Balance Sheet

Total Assets (Quarterly) 2.243B
Total Liabilities (Quarterly) 367.58M
Shareholders Equity (Quarterly) 1.875B
Cash and Short Term Investments (Quarterly) 1.815B
Total Long Term Assets (Quarterly) Upgrade
Total Long Term Debt (Quarterly) 0.00
Book Value (Quarterly) Upgrade

Earnings Quality

Return on Assets Upgrade
Return on Equity Upgrade
Return on Invested Capital Upgrade

Cash Flow

Cash from Operations (TTM) -495.74M
Cash from Investing (TTM) -258.66M
Cash from Financing (TTM) 38.59M
Change in Receivables (TTM) Upgrade
Changes in Working Capital (TTM) Upgrade
Capital Expenditures (TTM) Upgrade
Ending Cash (Quarterly) Upgrade
Free Cash Flow -532.93M

Profitability

Operating Margin (TTM) Upgrade
Gross Profit Margin Upgrade
Performance, Risk and Estimates

Stock Price Performance

1 Month Total Returns (Daily) Upgrade
3 Month Total Returns (Daily) Upgrade
6 Month Total Returns (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) -31.49%
Annualized 3 Year Total Returns (Daily) Upgrade
Annualized 5 Year Total Returns (Daily) Upgrade
Annualized 10 Year Total Returns (Daily) Upgrade
Annualized 15 Year Total Returns (Daily) Upgrade
Annualized All Time Total Returns (Daily) Upgrade
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
52-Week High Date Jul. 20, 2022
52-Week Low Date Dec. 30, 2022

Estimates

Revenue Estimates for Current Quarter Upgrade
Revenue Estimates for Next Quarter Upgrade
Revenue Estimates for Current Fiscal Year Upgrade
Revenue Estimates for Next Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade

Dividends and Shares

Dividend Yield 0.00%
Dividend Yield (Forward) Upgrade
Payout Ratio Upgrade
Cash Dividend Payout Ratio Upgrade
Last Dividend Amount --
Last Ex-Dividend Date --

Management Effectiveness

Asset Utilization (TTM) Upgrade
Days Sales Outstanding (Quarterly) Upgrade
Days Inventory Outstanding (Quarterly) Upgrade
Days Payable Outstanding (Quarterly) Upgrade
Total Receivables (Quarterly) Upgrade

Current Valuation

Market Cap 3.553B
Enterprise Value 1.738B
Price 45.18
PE Ratio --
PE Ratio (Forward) Upgrade
PE Ratio (Forward 1y) Upgrade
PS Ratio 8056.14
PS Ratio (Forward) Upgrade
PS Ratio (Forward 1y) Upgrade
Price to Book Value 1.895
Price to Free Cash Flow Upgrade
PEG Ratio Upgrade
EV to EBITDA Upgrade
EV to EBITDA (Forward) Upgrade
EV to EBIT Upgrade
EBIT Margin (TTM) Upgrade

Risk Metrics

Alpha (5Y) Upgrade
Beta (5Y) Upgrade
Annualized Standard Deviation of Monthly Returns (5Y Lookback) Upgrade
Historical Sharpe Ratio (5Y) Upgrade
Historical Sortino (5Y) Upgrade
Max Drawdown (5Y) 81.34%
Monthly Value at Risk (VaR) 5% (5Y Lookback) Upgrade
Other Metrics

Advanced Metrics

Piotroski F Score (TTM) Upgrade
Sustainable Growth Rate (TTM) Upgrade
Tobin's Q (Approximate) (Quarterly) Upgrade
Momentum Score Upgrade
Market Cap Score Upgrade
Quality Ratio Score Upgrade

Liquidity And Solvency

Debt to Equity Ratio 0.00
Free Cash Flow (Quarterly) -119.52M
Current Ratio Upgrade
Quick Ratio (Quarterly) Upgrade
Altman Z-Score (TTM) Upgrade
Times Interest Earned (TTM) Upgrade

Employee Count Metrics

Total Employees (Annual) Upgrade
Revenue Per Employee (Annual) Upgrade
Net Income Per Employee (Annual) Upgrade